|
| Title | Condition | Biological intervention | Drug combo | 1st line versus 2nd line versus adjuvant | Identifier | Comments |
|
| A study with neoadjuvant mFOLFOX7 plus cetuximab to determine the surgical conversion rate for unresectable colorectal cancer with metastasis confided to the liver (2008) | Metastatic colorectal cancer | Cetuximab | FOLFOX | Neoadjuvant | NCT00803647 | Surgical candidates only |
|
| Phase 2A study of NPC-1C chimeric monoclonal antibody to treat pancreatic and colorectal cancer (2009)* | Metastatic colorectal cancer; metastatic pancreatic cancer | NPC-1C (ensituximab) | | 2nd line | NCT01040000 | Refractory to standard treatment |
|
| EMD 5257 in combination with cetuximab and irinotecan in K-RAS Wild-type metastatic colorectal cancer (2009)** | Metastatic colorectal cancer | EMD525797 and cetuximab | irinotecan | 2nd line | NCT008475 | Randomized, no placebo |
|
| Dual Epidermal growth factor receptor inhibition with erlotinib and panitumumab with or without chemotherapy for advanced colorectal cancer (2009) | Colorectal cancer | Panitumumab + erlotinib | irinotecan | 2nd line | NCT00940316 | Refractory to FOLFOX |
|
| Irinotecan hydrochloride and cetuximab with or without ramucirumab in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy (2010) | Colorectal cancer | Cetuximab and ramucirumab | irinotecan | 2nd line | NCT01079780 | Refractory to bevacizumab containing chemotherapy |
|
| A study of IMC-1121b or IMC-18f1 in colorectal cancer (2010) | Colon cancer
Rectal cancer | IMC-1121b + IMC-18F1 | mFOLFOX-6 | 2nd line | NCT01111604 | Refractory to irinotecan-based first-line chemotherapy |
|
| A study of perioperative chemotherapy plus panitumumab in patients with colorectal cancer liver metastases (2010) | Colorectal cancer;
liver metastasis | Panitumumab | oxaliplatin, 5-FU | Neoadjuvant | NCT01260415 | Surgical candidates only |
|
| FOLFOXIRI plus panitumumab patients with metastatic KRAS wild-type colorectal cancer with liver metastases only (2010) | Colorectal cancer | Panitumumab | FOLFOXIRI | 1st line | NCT01226719 | Nonrandomized, no placebo |
|
| Study of first-line single-agent panitumumab in frail elderly patients with advanced wild-type K-RAS colorectal cancer (FRAIL) (2010) | Colorectal cancer | Panitumumab | | 1st line | NCT01126112 | Nonrandomized, no placebo |
|
| Study of panitumumab-capecitabine oxaliplatin in wild-type K-RAS colorectal cancer patients (2010) | Metastatic colorectal cancer | Panitumumab | Capecitabine/oxaliplatin | 1st line | NCT01215539 | Nonrandomized, no placebo |
|
| Study assessing potential predictive tumor markers in metastatic colorectal cancer (PULSE) (2010) | Metastatic colorectal cancer | Panitumumab | FOLFOX | 2nd line | NCT01288339 | Wild-type K-RAS according to IGFRp and MMP-7 expression |
|
| Panitumumab and bortezomib for patients with advanced colorectal cancer (2011) | Colorectal cancer | Panitumumab + bortezomib | | 2nd line | NCT01504477 | Refractory to standard treatment |
|
| Efficacy and safety of GS-6624 with FOLFIRI as second-line treatment in colorectal adenocarcinoma (2011) | Colorectal cancer | GS-6624 | FOLFIRI | 2nd line | NCT01479465 | Randomized, placebo-controlled |
|
| Neoadjuvant radiochemotherapy combined with panitumumab in locally advanced KRAS wild-type rectal cancer (NEOREC-1) (2011) | Rectal cancer | Panitumumab | | Neoadjuvant | NCT01443377 | Surgical candidates only |
|
| Safety study of the combination of panitumumab, irinotecan, and everolimus in the treatment of advanced colorectal cancer (PIE) (2011) | Colorectal cancer | Panitumumab | Everolimus, irinotecan | 2nd line | NCT01139138 | FOLFOX refractory |
|
| FOLFOXIRI plus panitumumab in K-RAS and BRAF wild-type metastatic colorectal cancer (TRIP) (2011) | Metastatic colorectal cancer | Panitumumab | FOLFOXIRI | 1st line | NCT01358812 | K-RAS and BRAF wild-type; nonrandomized, no placebo |
|
| FOLFOXIRI with or without panitumumab in metastatic colorectal cancer (VOLFI) (2011) | Metastatic colorectal cancer | Panitumumab | FOLFOXIRI | 2nd line | NCT01328171 | Randomized, no placebo |
|
